ArticleVirology journal2025
Trends in the molecular epidemiology of human papillomavirus in males from the plateau region of Southwest China: an 11-year retrospective analysis (2014-2024).
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Demographic and Screening-to-Diagnosis Cascade Indicators for Risk Stratification in an Organized Cervical Cancer Screening Program: Evidence from 82,141 Women in Yunnan, China.International journal of women's health · 2026Article
- HPV Prevalence and Genotype Distribution Among Infertile and Fertile Women of Turkish Nationality and Association with Cytology and Vaccination Status.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
backgroundPersistent high-risk human papillomavirus (HR-HPV) infection may increase the risk of malignancies in males, including penile, rectal, anal, prostate, bladder, and oropharyngeal cancers. However, few studies focused on the epidemiology of human papillomavirus (HPV) in male patients. This study aims to retrospectively investigate the trends of HPV molecular epidemiology in males residing in the plateau region of Southwest China from 2014 to 2024.
methodsThis retrospective study investigated the trends of HPV molecular epidemiology in 3580 males residing in the plateau region of southwest China from 2014 to 2024. Samples were collected for DNA extraction, and detection of 27 HPV genotypes by Luminex xMAP technology.
resultsHPV prevalence fluctuated between 43.17% and 56.02% over the 11 years, with an average prevalence of 50.28% (1800/3580, 95% CI: 48.64%-51.92%). Among infected individuals, LR-HPV alone, HR-HPV alone, and mixed infection accounted for 71.00%, 9.83%, and 19.17%, respectively. Single, dual, triple, quadruple, and other multiple infections accounted for 73.22%, 18.28%, 5.33%, 2.22%, and 0.95%, respectively. HPV prevalence varied by clinical diagnosis: the highest in warts (76.99%, 1114/1447), followed by neoplasms (67.15%, 92/137), other diagnoses (39.10%, 364/931), rash (30.17%, 73/242), urinary inflammation (24.23%, 47/194), and asymptomatic individuals (17.49%, 110/629). Age-specific HPV prevalence exhibited a U-shaped bimodal pattern. The top five HR-HPV genotypes were HPV16 (2.35%), HPV59 (2.18%), HPV52 (1.68%), HPV56 (1.54%), and HPV39 (1.48%), while the top three LR-HPV genotypes were HPV6 (26.45%), HPV11 (16.82%), and HPV43 (1.98%). The coverage rates of the currently available bivalent, quadrivalent, and nonavalent HPV vaccines were 5.18%, 66.84%, and 73.17%, respectively. However, these vaccines do not cover HPV51, HPV39, HPV59, HPV56, HPV53, HPV43, and HPV61, which are highly prevalent genotypes in the Chinese population.
conclusionThese findings highlight the urgent need for developing and promoting HPV vaccines tailored to the Chinese population and accelerating HPV vaccination programs among adolescents. Integrating male HPV vaccination into the national immunization program could significantly reduce the burden of HPV-related infections and diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.